Richard B. Pearson

17.9k total citations · 5 hit papers
136 papers, 12.4k citations indexed

About

Richard B. Pearson is a scholar working on Molecular Biology, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Richard B. Pearson has authored 136 papers receiving a total of 12.4k indexed citations (citations by other indexed papers that have themselves been cited), including 115 papers in Molecular Biology, 30 papers in Oncology and 16 papers in Pathology and Forensic Medicine. Recurrent topics in Richard B. Pearson's work include Protein Kinase Regulation and GTPase Signaling (34 papers), PI3K/AKT/mTOR signaling in cancer (27 papers) and RNA modifications and cancer (21 papers). Richard B. Pearson is often cited by papers focused on Protein Kinase Regulation and GTPase Signaling (34 papers), PI3K/AKT/mTOR signaling in cancer (27 papers) and RNA modifications and cancer (21 papers). Richard B. Pearson collaborates with scholars based in Australia, United States and Switzerland. Richard B. Pearson's co-authors include Bruce E. Kemp, Ross D. Hannan, Katherine M. Hannan, Grant A. McArthur, Wayne A. Phillips, Patrick B. Dennis, Elaine Sanij, Karen E. Sheppard, Anthony R. Means and Briony E. Cristiano and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Richard B. Pearson

135 papers receiving 12.2k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

[3] Protein kinase phosphorylation site sequences and consensus specificity motifs: Tabulations

1991 942 citations Richard B. Pearson, Bruce E. Kemp profile →
Protein kinase recognition sequence motifs

1990 910 citations Bruce E. Kemp, Richard B. Pearson profile →
Mutation of the PIK3CA Gene in Ovarian and Breast Cancer

2004 740 citations Ian Campbell, Briony E. Cristiano et al. Cancer Research profile →
A potent synthetic peptide inhibitor of the cAMP-dependent protein kinase.

1986 558 citations Bruce E. Kemp, Richard B. Pearson et al. profile →
Ribosomal proteins and human diseases: molecular mechanisms and targeted therapy

2021 214 citations Jian Kang, Natalie Brajanovski et al. profile →

Peers

Countries citing papers authored by Richard B. Pearson

Since Specialization

Citations

This map shows the geographic impact of Richard B. Pearson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard B. Pearson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard B. Pearson more than expected).

Fields of papers citing papers by Richard B. Pearson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard B. Pearson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard B. Pearson. The network helps show where Richard B. Pearson may publish in the future.

Co-authorship network of co-authors of Richard B. Pearson

This figure shows the co-authorship network connecting the top 25 collaborators of Richard B. Pearson. A scholar is included among the top collaborators of Richard B. Pearson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard B. Pearson. Richard B. Pearson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Spatial analysis with SPIAT and spaSim to characterize and simulate tissue microenvironments 2023 ·Nature Communications ·(unknown), Tianpei Yang, (unknown), (unknown), Maria Doyle, (unknown), (unknown), Angela Pizzolla, (unknown), (unknown), Anupama Pasam, (unknown), Yukuan Huang, Simon P. Keam, Terence P. Speed, Paul J. Neeson, Richard B. Pearson, Shahneen Sandhu, David L. Goode, Anna Trigos	38
2	CX-5461 Sensitizes DNA Damage Repair–proficient Castrate-resistant Prostate Cancer to PARP Inhibition 2021 ·Molecular Cancer Therapeutics ·Mitchell G. Lawrence, Laura H. Porter, (unknown), David Pook, Jeremy Grummet, Carmel Pezaro, Shahneen Sandhu, Susanne Ramm, (unknown), Andrew Bakshi, David L. Goode, Elaine Sanij, Richard B. Pearson, Ross D. Hannan, Kaylene J. Simpson, Renea A. Taylor, Gail P. Risbridger, Luc Furic	17
3	Impaired ribosome biogenesis checkpoint activation induces p53-dependent MCL-1 degradation and MYC-driven lymphoma death 2021 ·Blood ·(unknown), Suresh Peddigari, Carol A. Mercer, (unknown), (unknown), (unknown), Virginia Amador, Sarah T. Diepstraten, Gemma L. Kelly, Ramón Salazar, Sara C. Kozma, Eric Kusnadi, Jian Kang, Antonio Gentilella, Richard B. Pearson, George Thomas, Joffrey Pelletier	17
4	Suppression of ABCE1-Mediated mRNA Translation Limits N-MYC–Driven Cancer Progression 2020 ·Cancer Research ·Jixuan Gao, MoonSun Jung, Chelsea Mayoh, (unknown), Katherine M. Hannan, Jamie I. Fletcher, Alvin Kamili, Andrew J. Gifford, Eric Kusnadi, Richard B. Pearson, Ross D. Hannan, Michelle Haber, Murray D. Norris, Klaartje Somers, Michelle J. Henderson	18
5	Reprogrammed mRNA translation drives resistance to therapeutic targeting of ribosome biogenesis 2020 ·The EMBO Journal ·Eric Kusnadi, Anna Trigos, Carleen Cullinane, David L. Goode, Ola Larsson, Jennifer R. Devlin, Keefe T. Chan, David P. De Souza, Malcolm J. McConville, Grant A. McArthur, George Thomas, Elaine Sanij, Gretchen Poortinga, Ross D. Hannan, Katherine M. Hannan, Jian Kang, Richard B. Pearson	28
6	First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study 2019 ·Cancer Discovery ·Amit Khot, Natalie Brajanovski, Donald P. Cameron, Nadine Hein, Kylee Maclachlan, Elaine Sanij, John K. C. Lim, John Soong, Emma Link, Piers Blombery, Ella R. Thompson, Andrew Fellowes, Karen E. Sheppard, Grant A. McArthur, Richard B. Pearson, Ross D. Hannan, Gretchen Poortinga, Simon J. Harrison	132
7	Changes in long-range rDNA-genomic interactions associate with altered RNA polymerase II gene programs during malignant transformation 2019 ·Communications Biology ·Jeannine Diesch, Megan J. Bywater, Elaine Sanij, Donald P. Cameron, William Schierding, Natalie Brajanovski, Jinbae Son, (unknown), Nadine Hein, M. Evers, Richard B. Pearson, Grant A. McArthur, Austen R. D. Ganley, Justin M. O’Sullivan, Ross D. Hannan, Gretchen Poortinga	32
8	RNA Polymerase 1 Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Malignancies: Results of a Phase I First in Human Study 2017 ·Blood ·Amit Khot, Natalie Brajanovski, Donald P. Cameron, Gretchen Poortinga, Elaine Sanij, (unknown), John Soong, Nadine Hein, Emma Link, Richard B. Pearson, Ross D. Hannan, Grant A. McArthur, Simon J. Harrison	2
9	The Potential of Targeting Ribosome Biogenesis in High-Grade Serous Ovarian Cancer 2017 ·International Journal of Molecular Sciences ·Shunfei Yan, Daniel Frank, Jinbae Son, Katherine M. Hannan, Ross D. Hannan, Keefe T. Chan, Richard B. Pearson, Elaine Sanij	19
10	Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition 2016 ·Clinical Cancer Research ·George Au‐Yeung, (unknown), Walid J. Azar, Thomas J. Mitchell, Kate E. Jarman, Kurt Lackovic, (unknown), Carleen Cullinane, Richard B. Pearson, Linda Mileshkin, Danny Rischin, Alison M. Karst, Ronny Drapkin, Dariush Etemadmoghadam, David D.L. Bowtell	100
11	The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer 2016 ·Clinical Cancer Research ·Richard J. Rebello, Eric Kusnadi, Donald P. Cameron, Helen Pearson, (unknown), Jennifer R. Devlin, Denis Drygin, Ashlee K. Clark, Laura H. Porter, John Pedersen, Shahneen Sandhu, Gail P. Risbridger, Richard B. Pearson, Ross D. Hannan, Luc Furic	61
12	Combining High-Content Imaging and Phenotypic Classification Analysis of Senescence-Associated Beta-Galactosidase Staining to Identify Regulators of Oncogene-Induced Senescence 2016 ·Assay and Drug Development Technologies ·Keefe T. Chan, Lassi Paavolainen, Katherine M. Hannan, Amee J. George, Ross D. Hannan, Kaylene J. Simpson, Péter Horváth, Richard B. Pearson	8
13	The dual inhibition of RNA Pol I transcription and PIM kinase as a new therapeutic approach to treat advanced prostate cancer 2016 ·European Journal of Cancer ·Richard J. Rebello, Eric Kusnadi, Donald P. Cameron, Helen Pearson, (unknown), Jennifer R. Devlin, Denis Drygin, Abbe R. Clark, Lisa A. Porter, (unknown), Shahneen Sandhu, Gail P. Risbridger, Richard B. Pearson, Ross D. Hannan, Luc Furic	10
14	Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma 2015 ·Cancer Discovery ·Jennifer R. Devlin, Katherine M. Hannan, Nadine Hein, Carleen Cullinane, Eric Kusnadi, Pui Yee Ng, Amee J. George, Jake Shortt, Megan J. Bywater, Gretchen Poortinga, Elaine Sanij, Jian Kang, Denis Drygin, Sean O’Brien, Ricky W. Johnstone, Grant A. McArthur, Ross D. Hannan, Richard B. Pearson	91
15	Functional Analysis of Genes in Regions Commonly Amplified in High-Grade Serous and Endometrioid Ovarian Cancer 2013 ·Clinical Cancer Research ·(unknown), Karen E. Sheppard, Richard B. Pearson, Ian Campbell, Kylie L. Gorringe, Kaylene J. Simpson	51
16	The mTORC1 Inhibitor Everolimus Prevents and Treats Eμ- Myc Lymphoma by Restoring Oncogene-Induced Senescence 2012 ·Cancer Discovery ·Meaghan Wall, Gretchen Poortinga, Kym L. Stanley, Ralph K. Lindemann, Michael Bots, Christopher J. Chan, Megan J. Bywater, Kathryn M. Kinross, Megan V. Astle, Kelly Waldeck, Katherine M. Hannan, Jake Shortt, Mark J. Smyth, Scott W. Lowe, Ross D. Hannan, Richard B. Pearson, Ricky W. Johnstone, Grant A. McArthur	52
17	Coordinate regulation of ribosome biogenesis and function by the ribosomal protein S6 kinase, a key mediator of mTOR function 2007 ·Growth Factors ·Katarzyna Jastrzebski, Katherine M. Hannan, (unknown), Ross D. Hannan, Richard B. Pearson	186
18	A Specific Role for AKT3 in the Genesis of Ovarian Cancer through Modulation of G2-M Phase Transition 2006 ·Cancer Research ·Briony E. Cristiano, (unknown), Katherine M. Hannan, (unknown), (unknown), Ian Campbell, Wayne A. Phillips, Melissa Robbie, Ross D. Hannan, Richard B. Pearson	84
19	Dual Requirement for a Newly Identified Phosphorylation Site in p70 ^s6k 1997 ·Molecular and Cellular Biology ·Bettina A. Moser, Patrick B. Dennis, Nick Pullen, Richard B. Pearson, Nicholas A. Williamson, Richard E.H. Wettenhall, Sara C. Kozma, George Thomas	89
20	SUBSTRATE-SPECIFICITY OF A MULTIFUNCTIONAL CALMODULIN-DEPENDENT PROTEIN-KINASE 1985 ·Discovery Research Portal (University of Dundee) ·Bruce E. Kemp, Richard B. Pearson, James R. Woodgett, Pinchas Cohen	20

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact